Fuseya et al. [58] have found that systemic administration of QX-314 in mice could inhibit some behavioral aspects of bone cancer pain through selective inhibition of TRPV1-expressing afferents without coadministration of TRPV1 agonists. Here, TRPV1 is linked to bone cancer.